Home › Funds › Monaco Asset Management SAM › LKFT

Monaco Asset Management SAM position in LKFT

LAKEFRONT BIOTHERAPEUTICS NV

Monaco Asset Management SAM reported holding 20,000 shares of LKFT (LAKEFRONT BIOTHERAPEUTICS NV) in its Q3 2026 13F filing — a position valued at US$593K, representing 0.08% of its reported portfolio and ranking #38 among its reported holdings. Monaco Asset Management SAM has disclosed LKFT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)20.00K sh
Reported value held$593.00K
Portfolio Weight0.08%
First reportedQ3 2023
Last changeReduce
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How Monaco Asset Management SAM's LKFT position evolved

Monaco Asset Management SAM first disclosed a stake in LKFT in Q3 2023 at 8,458 shares (US$292K). The position peaked in Q3 2025 at 33,536 shares, worth US$1.2M. Across 13 filings, Monaco Asset Management SAM increased the stake 3 time(s), trimmed it 7 time(s) and left it unchanged 2 time(s). The most recent filing (Q3 2026) shows 20,000 shares valued at US$593K — a reduction of -5,600 shares quarter over quarter.. Notable position changes include a 148% increase in Q1 2024 (shares fell 23% over the following quarter), a 29% trim in Q4 2024 (shares fell 9% over the following quarter), a 140% increase in Q1 2025 (shares rose 11% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 8.46K $292.22K New
Q4 2023 6.74K $274.14K Reduce
Q1 2024 16.74K $539.16K Add
Q2 2024 21.00K $520.36K Add
Q3 2024 21.00K $604.56K Hold
Q4 2024 15.00K $412.50K Reduce
Q1 2025 36.04K $905.22K Add
Q2 2025 36.04K $1.01M Hold
Q3 2025 33.54K $1.16M Reduce
Q4 2025 32.52K $1.06M Reduce
Q1 2026 27.52K $825.60K Reduce
Q2 2026 25.60K $767.49K Reduce
Q3 2026 20.00K $593.00K Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About LKFT and 13F data

LKFT (LAKEFRONT BIOTHERAPEUTICS NV) is a company whose sector is not yet classified in our data. 19 other funds we track also report a position in LKFT — the largest reported positions include GILEAD SCIENCES, INC. (US$501.3M), TANG CAPITAL MANAGEMENT LLC (US$113.5M), Madison Avenue Partners, LP (US$103.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding LKFT

All LKFT fund holders →

FAQ

How long has Monaco Asset Management SAM held LKFT?

Monaco Asset Management SAM has disclosed LKFT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is Monaco Asset Management SAM's current position in LKFT?

As of Q3 2026, Monaco Asset Management SAM holds 20.00K shares of LKFT (LAKEFRONT BIOTHERAPEUTICS NV), valued at $593.00K, representing 0.08% of its reported portfolio and ranking #38.

Has Monaco Asset Management SAM been buying or selling LKFT?

In the latest 13F filing (Q3 2026), Monaco Asset Management SAM reduced its position in LKFT. The position peaked in Q3 2025 at 33.54K shares.

Which other funds hold LKFT?

Other major institutional holders of LKFT include GILEAD SCIENCES, INC., TANG CAPITAL MANAGEMENT LLC, Madison Avenue Partners, LP, among 19 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.